Skip to main content
. 2024 Jan 25;2024:8861126. doi: 10.1155/2024/8861126

Table 3.

Anthropometric values, laboratory findings, and Medscore among NAFLD patients and healthy controls at baseline (T0) and at the end of the study (T12): means (SD) and ΔT0–T12 as means (SD) in the differences of the values at T0 and at T12.

NAFLD patients (58) Healthy controls (73)
T0 T12 ΔT0–T12 P T0 T12 ΔT0–T12 P
BMI (kg/m2) 31.4 (5.5) 30.5 (5.6) 0.9 (1.2)§ <0.001 24.0 (3.8) 24.0 (3.8) 0.0 (0.9)§ 0.97
Waist circumference (cm) 105 (14) 104 (13) 0.9 (4.7)# 0.16 87 (11) 88 (11) −0.8 (3.8)# 0.04
Total cholesterol (mg/dL) 207 (34) 211 (35) −3.6 (28) 0.29 196 (40) 200 (35) −4.4 (24) 0.13
 HDL 50 (12) 53 (14) −3.2 (7.5) <0.01 66 (18) 66 (17) −0.4 (8.1) 0.43
 LDL 128 (31) 132 (29) −3.7 (23) 0.22 114 (38) 117 (34) −3.1 (22) 0.17
Triglycerides (mg/dL) 152 (96) 128 (58) 24 (76) 0.06 82 (39) 86 (43) −4.1 (31) 0.60
Glycemia (mg/dL) 98 (19) 99 (20) −0.5 (14) 0.57 85 (9) 85 (10) 0.2 0.47
Insulinemia (μU/mL) 16 (15) 13 (9) 2.4 (11) 0.12 5 (4) 5 (4) −0.1 0.94
AST (U/L) 22 (10) 22 (8) 0.2 0.71 19 (7) 21 (8) −1.4 (7) 0.05
ALT (U/L) 41 (21) 40 (21) 1.6 (21) 0.43 29 (19) 30 (19) −0.7 (15) 0.35
HOMA-IR index 3.9 (4.5) 3.6 (3.2) 0.3 (4.2) 0.23 1.1 (0.9) 1.1 (0.9) 0.0 0.86
Medscore 12 (3) 16 (3) −3.2 (3.1)§ <0.001 15 (4) 15 (4) −0.2§ 0.20

§ P < 0.001 and #P < 0.01 for the comparison between the differences among NAFLD patients and healthy controls (according to Wilcoxon nonparametric test for paired data). Mann–Whitney test.